(Q37626132)

21 August 2017

1 reference

title

Subcutaneous immunoglobulin: opportunities and outlook (English)

1 reference

21 August 2017

S Misbah

1

1 reference

21 August 2017

M H Sturzenegger

2

1 reference

21 August 2017

M Borte

3

1 reference

21 August 2017

R S Shapiro

4

1 reference

21 August 2017

R L Wasserman

5

1 reference

21 August 2017

M Berger

6

1 reference

21 August 2017

H D Ochs

7

1 reference

21 August 2017

language of work or name

1 reference

1 December 2009

1 reference

21 August 2017

number of pages

9

1 reference

Clinical and Experimental Immunology

inferred from page(s)

published in

1 reference

21 August 2017

volume

158 Suppl 1

1 reference

21 August 2017

page(s)

51-59

1 reference

Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.

21 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Subcutaneous administration of IgG.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Intravenous immunoglobulin: adverse reactions and management

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Intravenous immunoglobulin in immunodeficiency states: state of the art.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Intravenous immunoglobulin for multifocal motor neuropathy

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Chronic inflammatory demyelinating polyneuropathy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Multifocal motor neuropathy: current concepts and controversies.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Immunoglobulin therapy: history, indications, and routes of administration

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

How long is IVIg effective in multifocal motor neuropathy?

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Multifocal motor neuropathy with conduction block: a study of 24 patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801034

Express subcutaneous IgG infusions: decreased time of delivery with maintained safety

1 September 2018

1 reference

12 December 2020

Consensus criteria for the diagnosis of multifocal motor neuropathy

1 reference

12 December 2020

Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance

1 reference

12 December 2020

1 reference

12 December 2020

Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study

1 reference

12 December 2020

A recombinant human enzyme for enhanced interstitial transport of therapeutics

1 reference

12 December 2020

Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies

1 reference

12 December 2020

[Long-term follow-up of multifocal motor neuropathy with conduction block under intravenous immunoglobulin]

1 reference

12 December 2020

Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

1 reference

12 December 2020

Hyaluronidase as a factor hastening the spread and absorption of water-soluble radiopaque substances deposited intracutaneously, subcutaneously and intramuscularly

1 reference

12 December 2020

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

1 reference

12 December 2020

Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

1 reference

12 December 2020

Clinical uses of intravenous immune globulin.

1 reference

12 December 2020

Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency

1 reference

12 December 2020

Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study

1 reference

12 December 2020

10.1111/J.1365-2249.2009.04027.X

Identifiers

DOI

1 reference

21 August 2017

0 references

1 reference